First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)

被引：0
|
作者：
Levi, Francis
Ducreux, Michel
Hebbar, Mohamed
Rougier, Philippe
Focan, C. N. J.
Guimbaud, Rosine
Carvalho, Carlos
Tumolo, Salvatore
Innominato, Pasquale F.
Ajavon, Yves
Castaing, Denis
De Baere, Thierry
Karaboue, Abdoulaye
Lepere, Celine
Boige, Valerie
Proux, Laetitia
Adam, Rene
Bouchahda, Mohamed
机构：
[1] Hop Paul Brousse, Dept Med Oncol, INSERM U776, Villejuif, France
[2] Inst Gustave Roussy, Villejuif, France
[3] Ctr Hosp Reg & Univ Lille, Hop Huriez, Med Oncol Unit, F-59037 Lille, France
[4] European Hosp George Pompidou, Paris, France
[5] CHC Clin St Joseph, Liege, Belgium
[6] Univ Hosp Purpan, Toulouse, France
[7] Hosp Fernando Fonesca Amadora, Med Oncol Unit, Amadora, Portugal
[8] Santa Maria Degli Angeli Gen Hosp, Pordenone, Italy
[9] Hop Paul Brousse, Inserm U776, Dept Cancerol, Villejuif, France
[10] Hop Paul Brousse, Serv Radiol, Villejuif, France
[11] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France
[12] Hop Paul Brousse, INSERM U776, Villejuif, France
[13] Inst Gustave Roussy, Serv Hepatogastroenterol, Villejuif, France
[14] CRESGE, Lille, France
[15] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3547
引用
收藏
页数：1
相关论文
共 33 条
  • [1] Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).
    Levi, Francis
    Boige, Valerie
    Hebbar, Mohamed
    Smith, Denis
    Lepere, Celine
    Focan, C. N. J.
    Guimbaud, Rosine
    Carvalho, Carlos
    Tumolo, Salvatore
    Innominato, Pasquale F.
    Ajavon, Yves
    Truant, Stephanie
    Castaing, Denis
    De Baere, Thierry
    Kunstlinger, Francis
    Karaboue, Abdoulaye
    Bouchahda, Mohamed
    Rougier, Philippe R.
    Adam, Rene
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin plus intravenous cetuximab (Cet) (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) (European phase II clinical trial NCT00852228).
    Ducreux, Michel
    Innominato, Pasquale F.
    Hebbar, Mohamed
    Smith, Denis Michel
    Lepere, Celine
    Focan, C. N. J.
    Guimbaud, Rosine
    Carvalho, Carlos
    Tumolo, Salvatore
    Awad, Sameh
    Truant, Stephanie
    Castaing, Denis
    Karaboue, Abdoulaye
    De Baere, Thierry
    Kunstlinger, Francis
    Bouchahda, Mohamed
    Boige, Valerie
    Rougier, Philippe
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] SAFETY AND EFFICACY OF INTRAVENOUS CETUXIMAB (CET) AND HEPATIC ARTERY INFUSION OF IRINOTECAN, 5-FLUOROURACIL AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE LIVER METASTASES FROM WT KRAS COLORECTAL CANCER (CRC): RESULTS FROM OPTILIV EUROPEAN PHASE II TRIAL
    Levi, F.
    Boige, V.
    Rougier, P.
    Hebbar, M.
    Smith, D.
    Focan, C.
    Guimbaud, R.
    Carvalho, C.
    Bouchahda, M.
    Ducreux, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 194 - 194
  • [4] Chronomodulated hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil (5-FU), and oxaliplatin (l-OHP) plus intravenous (iv) cetuximab (Cet) (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after treatment failure (European Phase II trial NCT 00852228)
    Bouchahda, Mohamed
    Karaboue, Abdoulaye
    Etienne-Grimaldi, Marie-Christine
    Chatelut, Etienne
    Innominato, Pasquale F.
    Paintaud, Gilles
    Ricca, Luana
    Vibert, Eric
    Ajavon, Yves
    Awad, Sameh
    Castaing, Denis
    Focan, C. N. J.
    Milano, Gerard
    Morere, Jean Francois
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Early tumor shrinkage as a predictor for long-term outcome in patients (pts) with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion (HAI) of Irinotecan, 5-Fluorouracil and Oxaliplatin plus intravenous Cetuximab (IV-Cet) after failure of one to three systemic protocols (European phase II clinical trial NCT00852228)
    Bouchahda, M.
    Michel, D.
    Denis, S.
    Abdoulaye, K.
    Mohamed, H.
    Celine, L.
    Christian, F.
    Rosine, G.
    Pasquale, I.
    Sameh, A.
    Carlos, C.
    Salvatore, T.
    Stephanie, T.
    Thierry, D. B.
    Denis, C.
    Philippe, R.
    Valerie, B.
    Francois, M. Jean
    Rene, A.
    Francis, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S348 - S348
  • [6] Robustness of circadian rest-activity rhythm for predicting efficacy of intravenous cetuximab (Cet) and hepatic artery infusion (HAI) of chronomodulated irinotecan, 5-fluorouracil and oxaliplatin (Chrono-Optiliv) for liver metastases from colorectal cancer (LM-CRC) (Optiliv translational study, NCT00852228).
    Karaboue, Abdoulaye
    Innominato, Pasquale F.
    Bouchahda, Mohamed
    Mocquery, Magali
    Bossevot, Rachel
    Plessis, Virginie
    Bouchoucha, Davina
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
    Levi, Francis
    Ducreux, Michel
    Smith, Denis Michel
    Hebbar, Mohamed
    Lepere, Celine
    Focan, C. N. J.
    Guimbaud, Rosine
    Innominato, Pasquale F.
    Carvalho, Carlos
    Tumolo, Salvatore
    Truant, Stephanie
    Castaing, Denis
    Karaboue, Abdoulaye
    Boige, Valerie
    Bouchahda, Mohamed
    Rougier, Philippe
    Adam, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
    Francis Lévi
    Abdoulaye Karaboué
    Raphaël Saffroy
    Christophe Desterke
    Valerie Boige
    Denis Smith
    Mohamed Hebbar
    Pasquale Innominato
    Julien Taieb
    Carlos Carvalho
    Rosine Guimbaud
    Christian Focan
    Mohamed Bouchahda
    René Adam
    Michel Ducreux
    Gérard Milano
    Antoinette Lemoine
    British Journal of Cancer, 2017, 117 : 965 - 973
  • [9] Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
    Levi, Francis
    Karaboue, Abdoulaye
    Saffroy, Raphael
    Desterke, Christophe
    Boige, Valerie
    Smith, Denis
    Hebbar, Mohamed
    Innominato, Pasquale
    Taieb, Julien
    Carvalho, Carlos
    Guimbaud, Rosine
    Focan, Christian
    Bouchahda, Mohamed
    Adam, Rene
    Ducreux, Michel
    Milano, Gerard
    Lemoine, Antoinette
    BRITISH JOURNAL OF CANCER, 2017, 117 (07) : 965 - 973
  • [10] Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II trial.
    Ducreux, M.
    Rougier, P.
    Smith, D.
    Focan, C. N. J.
    Innominato, P. F.
    Bouchahda, M.
    Ajavon, Y.
    Castaing, D.
    De Baere, T.
    Karaboue, A.
    Lepere, C.
    Boige, V.
    Adam, R.
    Levi, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
1234